Medicine and Dentistry
Acute Myeloid Leukemia
100%
Overall Survival
68%
Malignant Neoplasm
54%
Hematopoietic Stem Cell
37%
Cell Transplantation
30%
Myeloproliferative Neoplasm
26%
Essential Thrombocythaemia
22%
Polycythemia vera
22%
Risk Stratification
22%
Disease
21%
Thrombocytopenia
21%
Acute Promyelocytic Leukemia
17%
Myelodysplastic Syndrome
17%
Venous Thromboembolism
17%
Myelodysplastic Syndrome
17%
Oncology
17%
Charlson Comorbidity Index
17%
Symptom
15%
Myelofibrosis
15%
Hazard Ratio
14%
Neoplasm
13%
Geriatric Assessment
11%
Clinical Trial
11%
Supportive Care
11%
Thrombotic Thrombocytopenic Purpura
10%
Proportional Hazards Model
9%
Macrocytosis
8%
Cerebral Venous Sinus Thrombosis
8%
Mean Corpuscular Volume
8%
Phosphotransferase
8%
Thrombocyte Factor 4
8%
Dalteparin Sodium
8%
Thrombosis
8%
Fusion Gene
8%
Protein Tyrosine Kinase
8%
Receptor
8%
Acute Lymphoblastic Leukemia
8%
Eosinophilia
8%
Systemic Mastocytosis
8%
Chemotherapy Agent
8%
Inotuzumab Ozogamicin
8%
Cohort Effect
8%
Health System
7%
Leukemia
7%
Transplantation
7%
Diagnosis
7%
Medicare
6%
Heparin-Induced Thrombocytopenia
6%
Philadelphia 1 Chromosome
6%
Decitabine
6%
Keyphrases
Acute Myeloid Leukemia
55%
Overall Survival
53%
Newly Diagnosed
26%
Chemotherapy
21%
NCCN Guidelines
20%
Older Patients
19%
Myeloproliferative Neoplasms
17%
Acute Promyelocytic Leukemia
17%
Older Adults
17%
Early Mortality
17%
Essential Thrombocythemia
17%
Polycythemia Vera
17%
Charlson Comorbidity Index
14%
Acute Lymphoblastic Leukemia
11%
Risk Stratification
11%
Hematopoietic Cell Transplantation
10%
Multi-agent
10%
Clinical Trials
10%
Mortality in Elderly
8%
Therapy Selection
8%
Red Cell Distribution Width
8%
Mean Corpuscular Volume
8%
Multiplicative Interaction
8%
Independent Predictors of Mortality
8%
Tissue-specific Enhancers
8%
Anticoagulation Reversal
8%
Thrombosis with Thrombocytopenia Syndrome
8%
Cryopreserved Platelets
8%
Platelet Count
8%
Tyrosine Kinase Fusions
8%
Myeloid/lymphoid Neoplasms with Eosinophilia
8%
Relapsed or Refractory
8%
Blinatumomab
8%
Myelofibrosis
8%
Geriatric Assessment
8%
T-AML
8%
Dalteparin
8%
Thrombocytosis
8%
Active Malignancy
8%
Match Result
8%
Venous Thromboembolic Disease
8%
Venous Thromboembolism
8%
Myelomagenesis
8%
Polypharmacy
8%
Cancer-related
8%
Gemtuzumab Ozogamicin
8%
Systemic Mastocytosis
8%
MicroRNA-21 (miR-21)
8%
Oncology
8%
Supportive Care
8%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
44%
Acute Myeloid Leukemia
26%
Disease
20%
Thrombocytopenia
19%
Promyelocytic Leukemia
17%
Thrombotic Thrombocytopenic Purpura
17%
Myelodysplastic Syndrome
17%
Phosphotransferase
17%
Prevalence
17%
Venous Thromboembolism
17%
Malignant Neoplasm
17%
Thrombocyte Factor 4
16%
Heparin Induced Thrombocytopenia
14%
Anticoagulant Agent
10%
Clinical Trial
10%
Megalocytosis
8%
Epidemiology
8%
Receptor
8%
Long Term Survival
8%
Transforming Growth Factor
8%
Dalteparin
8%
Polypharmacy
8%
Antivitamin K
8%
Thrombocytosis
8%
Hematologic Malignancy
8%
Growth Factor Receptor
8%
Inotuzumab Ozogamicin
8%
Blinatumomab
8%
Pegcetacoplan
8%
Enzyme-Linked Immunosorbent Assay
8%
Heparin
7%
Comorbidity
6%
Bleeding
6%
Chemotherapy
6%
Polyanion
5%
Thrombospondin 1
5%
Obesity
5%
